The eyes may be windows to the soul, but the nose is a gateway to the mucosal immune system. Drug companies are now developing vaccines to take advantage of that gateway.
|Courtesy of Aviron|
MISTING UP: Aviron's nasal flu vaccine, which has recently completed Phase III trials, targets the mucosal system and protects against both flu and ear infection.
Recombinant cholera toxin subunit B (rCTB) provides the heart of...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?